AR047373A1 - 3-oxohexahidrofuro(3,2-b)pirroles hidrogenados como inhibidores de catepsina k - Google Patents
3-oxohexahidrofuro(3,2-b)pirroles hidrogenados como inhibidores de catepsina kInfo
- Publication number
- AR047373A1 AR047373A1 ARP050100055A ARP050100055A AR047373A1 AR 047373 A1 AR047373 A1 AR 047373A1 AR P050100055 A ARP050100055 A AR P050100055A AR P050100055 A ARP050100055 A AR P050100055A AR 047373 A1 AR047373 A1 AR 047373A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- halo
- optionally substituted
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1), en donde: uno de R1 y R2 es halo y el otro es H o halo; R3 es C1-5 alquilo de cadena lineal o ramificada, optativamente fluorado; R4 es H; o R3 junto con R4 define un espiro-C5-7 cicloalquilo, opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de halo, hidroxilo, C1-4 alquilo o C1-4 haloalquilo; u opcionalmente tendiendo un puente con un grupo metileno; o un C4-6 heterociclo saturado que contiene un heteroátomo seleccionado entre O, NRa, S, S(=O)2; R5 se selecciona en forma independiente entre H o metilo; E es -C(=O)-, -S(=O)m-, -NR5S(=O)m-, -NR5C(=O)-, -OC(=O)-; R6 es un carbociclo o heterociclo, monocíclico o bicíclico, estable, opcionalmente sustituido en donde el o cada anillo tiene 4, 5 o 6 átomos en el anillo y 0 a 3 heteroátomos seleccionados entre S, O y N y en donde los sustituyentes opcionales comprenden 1 a 3 miembros seleccionados de R7; R7 se selecciona en forma independiente entre halo, oxo, nitrilo, nitro, C1-4 alquilo, -XNRaRb, -XNRbR9, -NRb(C1-4 alquil)R9, NH2CO-, X-R9, X-O-R9, O-X-R9, X-C(=O)R9, X-(C=O)NRaR9, X-NRbC(=O)R9, X-NHSOmR9, X-S(=O)mR9, X-C(=O)OR9, X-NRbC(=O)OR9; R9 es en forma independiente H, C1-4 alquilo, C3-6 cicloalquilo, pirrolidinilo, piperidinilo, morfolinilo, tiomorfolinilo, piperazinilo, indolinilo, piranilo, tiopiranilo, furanilo, tienilo, pirrolilo, oxazolilo, isoxazolilo, tiazolilo, imidazolilo, piridinilo, pirimidinilo, pirazinilo, indolilo, fenilo, cualquiera de los cuales está opcionalmente sustituido con R10; R10 se selecciona en forma independiente entre hidroxi, XR9, -XNRaRb, -XNRbR9, -NRb(C1-4)alquilR9, nitro, ciano, carboxi, oxo, C1-4 alquilo, C1-4 alcoxi, C1-4 alcanoilo, carbamoilo; X es en forma independiente un ligando o C1-4 alquilo; Ra es en forma independiente H, C1-4 alquilo o CH2C(=O); Rb es en forma independiente H, o C1-4 alquilo; m es en forma independiente 0, 1 o 2; o una sal farmacéuticamente aceptable o una prodroga de la misma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0400022A SE0400022D0 (sv) | 2004-01-08 | 2004-01-08 | New compounds |
| SE0401332A SE0401332D0 (sv) | 2004-05-26 | 2004-05-26 | New compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047373A1 true AR047373A1 (es) | 2006-01-18 |
Family
ID=34752290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100055A AR047373A1 (es) | 2004-01-08 | 2005-01-07 | 3-oxohexahidrofuro(3,2-b)pirroles hidrogenados como inhibidores de catepsina k |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7915300B2 (es) |
| EP (1) | EP1701960B1 (es) |
| JP (1) | JP4787765B2 (es) |
| AR (1) | AR047373A1 (es) |
| AT (1) | ATE461200T1 (es) |
| AU (1) | AU2005203972B2 (es) |
| BR (1) | BRPI0506719A (es) |
| CA (1) | CA2552739A1 (es) |
| DE (1) | DE602005019971D1 (es) |
| ES (1) | ES2341869T3 (es) |
| HK (1) | HK1096956A1 (es) |
| TW (1) | TWI343384B (es) |
| WO (1) | WO2005066180A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE461200T1 (de) | 2004-01-08 | 2010-04-15 | Medivir Ab | Inhibitoren von cysteinprotease |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| MX2007000762A (es) | 2004-07-22 | 2007-04-02 | Ptc Therapeutics Inc | Tienopiridinas para tratamientode hepatitis c. |
| GB0513840D0 (en) * | 2005-07-07 | 2005-08-10 | Medivir Ab | Cysteine protease inhibitors |
| GB0517279D0 (en) * | 2005-08-23 | 2005-10-05 | Amura Therapeutics Ltd | Biologically active compounds |
| KR20080066938A (ko) * | 2005-10-07 | 2008-07-17 | 깃세이 야쿠힌 고교 가부시키가이샤 | 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물 |
| GB0611654D0 (en) * | 2006-06-13 | 2006-07-19 | Medivir Ab | Compounds |
| GB0614073D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614042D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614046D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614044D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614037D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614052D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614053D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0618263D0 (en) * | 2006-09-18 | 2006-10-25 | Medivir Ab | Compound |
| WO2008114054A1 (en) * | 2007-03-19 | 2008-09-25 | Medivir Ab | Protease inhibitors |
| EP2168600A1 (en) | 2007-06-08 | 2010-03-31 | Nippon Chemiphar Co., Ltd. | Therapeutic or prophylactic agent for cerebral aneurysm |
| US7893067B2 (en) * | 2007-06-27 | 2011-02-22 | Medivir Ab | Cysteine protease inhibitors |
| ES2655534T3 (es) | 2007-08-13 | 2018-02-20 | Monsanto Technology Llc | Composiciones y procedimientos de control de nematodos |
| JPWO2009054454A1 (ja) | 2007-10-24 | 2011-03-03 | 国立大学法人 東京医科歯科大学 | カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤 |
| EP2719700A1 (en) | 2008-01-09 | 2014-04-16 | Amura Therapeutics Limited | Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases |
| GB0804701D0 (en) | 2008-03-13 | 2008-04-16 | Amura Therapeutics Ltd | Compounds |
| GB0817424D0 (en) | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
| GB0916608D0 (en) | 2009-09-22 | 2009-11-04 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US10087190B1 (en) * | 2017-04-24 | 2018-10-02 | Purdue Research Foundation | Lactones |
| US10995803B2 (en) | 2018-12-04 | 2021-05-04 | Means Industries, Inc. | Electromagnetic system for controlling the operating mode of a non friction coupling assembly and coupling and magnetic control assembly having same |
| WO2022147694A1 (en) * | 2021-01-06 | 2022-07-14 | Beijing Erai Therapeutics Co., Ltd. | Aminoheteroaryl compounds and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013079A1 (es) * | 1997-05-06 | 2000-12-13 | Smithkline Beecham Corp | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios |
| GB0003111D0 (en) | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
| ES2261341T3 (es) | 2000-11-17 | 2006-11-16 | Medivir Ab | Inhibidor de cisteina proteasa. |
| MXPA03006224A (es) * | 2001-01-17 | 2004-10-15 | Amura Therapeutics Ltd | Inhibidores de cruzipaina y otras proteasas de cisteina. |
| JP2003183161A (ja) * | 2001-12-21 | 2003-07-03 | Kitasato Inst:The | 骨粗鬆症の予防治療剤 |
| CA2548600A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| WO2005065578A2 (en) | 2004-01-06 | 2005-07-21 | Nicast Ltd. | Vascular prosthesis with anastomotic member |
| ATE461200T1 (de) | 2004-01-08 | 2010-04-15 | Medivir Ab | Inhibitoren von cysteinprotease |
| CA2552726A1 (en) | 2004-01-08 | 2005-07-21 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
| GB0513839D0 (en) | 2005-07-07 | 2005-08-10 | Medivir Ab | Cysteine protease inhibitors |
| GB0614052D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
-
2005
- 2005-01-06 AT AT05702148T patent/ATE461200T1/de not_active IP Right Cessation
- 2005-01-06 AU AU2005203972A patent/AU2005203972B2/en not_active Ceased
- 2005-01-06 JP JP2006548412A patent/JP4787765B2/ja not_active Expired - Fee Related
- 2005-01-06 ES ES05702148T patent/ES2341869T3/es active Active
- 2005-01-06 WO PCT/GB2005/050003 patent/WO2005066180A1/en active Application Filing
- 2005-01-06 US US10/584,930 patent/US7915300B2/en active Active
- 2005-01-06 BR BRPI0506719-7A patent/BRPI0506719A/pt not_active IP Right Cessation
- 2005-01-06 CA CA002552739A patent/CA2552739A1/en not_active Abandoned
- 2005-01-06 EP EP05702148A patent/EP1701960B1/en active Active
- 2005-01-06 DE DE602005019971T patent/DE602005019971D1/de active Active
- 2005-01-07 TW TW094100535A patent/TWI343384B/zh not_active IP Right Cessation
- 2005-01-07 AR ARP050100055A patent/AR047373A1/es not_active Application Discontinuation
-
2007
- 2007-02-09 HK HK07101596.9A patent/HK1096956A1/xx not_active IP Right Cessation
-
2011
- 2011-01-19 US US13/009,773 patent/US20110112089A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2552739A1 (en) | 2005-07-21 |
| TW200536847A (en) | 2005-11-16 |
| JP4787765B2 (ja) | 2011-10-05 |
| JP2007517852A (ja) | 2007-07-05 |
| TWI343384B (en) | 2011-06-11 |
| AU2005203972A1 (en) | 2005-07-21 |
| WO2005066180A9 (en) | 2008-09-25 |
| EP1701960A1 (en) | 2006-09-20 |
| US7915300B2 (en) | 2011-03-29 |
| US20110112089A1 (en) | 2011-05-12 |
| US20080234260A1 (en) | 2008-09-25 |
| DE602005019971D1 (de) | 2010-04-29 |
| HK1096956A1 (en) | 2007-06-15 |
| AU2005203972B2 (en) | 2010-11-18 |
| BRPI0506719A (pt) | 2007-05-02 |
| ES2341869T3 (es) | 2010-06-29 |
| EP1701960B1 (en) | 2010-03-17 |
| ATE461200T1 (de) | 2010-04-15 |
| WO2005066180A1 (en) | 2005-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047373A1 (es) | 3-oxohexahidrofuro(3,2-b)pirroles hidrogenados como inhibidores de catepsina k | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| PE20160044A1 (es) | Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos | |
| CO5700770A2 (es) | 1,4-diazepinas sustituidas y usos de las mismas | |
| AR049647A1 (es) | Cis-imidazolinas | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| CO6160266A2 (es) | Derivado de oxopirazina y herbicida | |
| AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
| CO6150159A2 (es) | Compuestos de heteroarilo utiles como inhibidores de enzimas de activacion e1 | |
| AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
| UY29844A1 (es) | Formulación en aerosol para la inhalación de beta-agonistas | |
| ECSP088150A (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| ECSP099638A (es) | Nuevo compuesto de adenina | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| AR057033A1 (es) | Tigeciclina y metodos para preparar 9-nitrominociclina | |
| AR044036A1 (es) | Compuestos de pirazolopirimidinas y pirazolopiridinas como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos | |
| AR054272A1 (es) | Derivados de 3- aminopirrilidinas tri, tetra - sustituidos | |
| AR052915A1 (es) | Derivados de pirrolidin y piperidin acetileno | |
| UY30387A1 (es) | Nuevos compuestos | |
| AR072726A1 (es) | Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c | |
| NI200800247A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
| SV2010003459A (es) | Derivados de pirimidina 934 | |
| AR049301A1 (es) | Procedimiento para la preparacion de compuestos de diarilisoxazol sulfonamida y productos intermedios | |
| AR094123A1 (es) | Compuesto triciclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |